API
< Back to situation

[REVISION HISTORY]

Pacira BioSciences corporate acquisitions

1 recorded revision of this situation.

What changed

2026-11-03 18:04 UTC → 2026-11-04 13:20 UTC · added removed

Pacira BioSciences has undergone significant structural changes through multiple acquisitions. In October 2026, Viatris entered a definitive agreement to acquire Pacira BioSciences in an all-cash transaction valued at approximately $1.65 billion. This acquisition aimed to incorporate Pacira’s non-opioid pain therapies, specifically Exparel and Zilretta, into the Viatris portfolio. Following this, in In November 2026, Zimmer Biomet agreed to acquire the Iovera business from Pacira BioSciences. This transaction, The deal is valued at up to $140 million, consisting of a $70 million including milestone payments, granted Zimmer Biomet the rights upfront payment and up to the $70 million in revenue-based milestone payments through 2031. The Iovera system uses cold therapy system. to provide targeted, non-opioid pain relief for patients with knee pain or those undergoing joint replacement surgery. This acquisition is intended to strengthen Zimmer Biomet’s orthopaedics portfolio. The sale was intended to allow Pacira BioSciences to focus on its core biopharmaceutical business and its existing pipeline of non-opioid pain therapies.

Versions

  1. 2026-11-04 13:20 UTC Pacira BioSciences corporate acquisitions
  2. 2026-11-03 18:04 UTC Pacira BioSciences corporate acquisitions

Select a version to see what changed compared to the one before it.